T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib)-Reference-Cited by-同舟云学术

T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib)

Published:2017-12-18 Issue:27 Volume:1 Page:2724-2728
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Li Geling¹^ORCID,Waite Emily²,Wolfson Julie³^ORCID

Affiliation:

1. Department of Pathology and Laboratory Medicine and

2. Department of Pharmacy, Children’s of Alabama, Birmingham, AL; and

3. Institute for Cancer Outcomes and Survivorship, School of Medicine, University of Alabama at Birmingham, Birmingham, AL

Abstract

Key Points A 19-year-old ataxia-telangiectasia patient with T-cell prolymphocytic leukemia harbored 2 JAK3-activating hotspot mutations. The patient suffered toxicities with chemotherapy, but demonstrated a clinical response to novel use of a JAK3 inhibitor (tofacitinib).

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/1/27/2724/879243/advances010470.pdf

Reference25 articles.

1. Inactivation of the ATM gene in T-cell prolymphocytic leukemias;Stoppa-Lyonnet;Blood,1998

2. Mature T-cell leukemias;Ravandi;Cancer,2005

3. Management of prolymphocytic leukemia;Dearden,2015

4. Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies;Suarez;J Clin Oncol,2015

5. Leukemia and lymphoma in ataxia telangiectasia;Taylor;Blood,1996

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. QSAR-driven screening uncovers and designs novel pyrimidine-4,6-diamine derivatives as potent JAK3 inhibitors;Journal of Biomolecular Structure and Dynamics;2023-12-07

2. JAK3 Y841 Autophosphorylation Is Critical for STAT5B Activation, Kinase Domain Stability and Dimer Formation;International Journal of Molecular Sciences;2023-07-25

3. Partial response to venetoclax and ruxolitinib combination in a case of refractory T-prolymphocytic leukemia;Hematology;2023-07-24

4. Discovery of Hexahydrofuro[3,2-b]furans as New Kinase-Selective and Orally Bioavailable JAK3 Inhibitors for the Treatment of Leukemia Harboring a JAK3 Activating Mutant;Journal of Medicinal Chemistry;2022-07-21

5. The natural history of ataxia-telangiectasia (A-T): A systematic review;PLOS ONE;2022-03-15